Belzutifan offers hope for patients with von Hippel-Lindau disease

The anti-cancer effect of the drug may help those with rare, hereditary cancer syndromes avoid surgeries by shrinking tumors via a daily oral dose.

5:00 AM

Author | Jordyn Imhoff

drawing in blue ink of kidneys on lined paper with lab note wording bottom right in blue with yellow background
Michigan Medicine

Patients with von Hippel–Lindau disease, a genetic condition brought on by a mutation in the VHL gene that predisposes the carrier to developing different kinds of tumors, have a high incidence of cancers, like kidney cancer. This is because of an inactive VHL gene that leads to hypoxia signaling, a condition that results from an imbalance between cellular oxygen consumption and blood flow.

Traditionally, invasive procedures like kidney and brain surgery were the only option for patients who produce these tumors, but an international single-group study of 61 participants published in The New England Journal of Medicine offers hope for those with the rare disease with the drug Belzutifan, which the research team showed can shrink tumors and keep patients from having to undergo surgery.

The drug, which targets the molecular defect in the VHL gene by antagonizing the hypoxia signaling, produces few side effects (predominantly anemia and/or fatigue) and appears to have an anti-cancer effect, according to study author Tobias Else, M.D., an endocrinologist leading the Comprehensive Clinical Care Center for VHL at University of Michigan Health Rogel Cancer Center.

"In virtually all of the patients' kidney cancers, brain and pancreatic tumors, the tumors shrunk and the effect was long lasting," said Else.

These findings are especially important for patients who are at higher risk of losing vital organ function due to tumors, or who face this risk due to the need to undergo major surgery. Belzutifan provides an alternative to surgery and may even replace it at some point, which is Else's hope.

"Ongoing studies will further evaluate the effect of this drug on these patients' tumors, but this is an exciting start for anyone with a hereditary cancer syndrome," said Else. "Rare diseases don't often get the attention they deserve, and this work shows that bench to bedside research can truly change peoples' lives. It may even lead to FDA approval of an entirely new in-class drug."

This research was sponsored by Peloton Therapeutics, Inc. and funded by Merck Sharp and Dohme, a subsidiary of Merck; the Intramural Research Program of the National Institutes of Health, National Cancer Institute Center for Cancer Research; and a grant (UO1 CA236489) from the NCI. ClinicalTrials.gov Identifier: NCT03401788.

Paper cited: "Belzutifan for Renal Cell Carcinoma in von Hippel–Lindau Disease," The New England Journal of Medicine. DOI: 10.1056/NEJMoa2103425


More Articles About: Lab Notes Basic Science and Laboratory Research Alternative Medicine Cancer: Cancer Types Cancer and Genetics Cancer Surgery Cancer Research Cancer Treatment Genetics Rogel Cancer Center Kidney Cancer Surgery Types All Research Topics
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of health care news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe
Featured News & Stories yellow tinted graphic moving with mouth opening seeing down throat red and tonsils in pink in back
Health Lab
Study finds tonsil removal not linked to undesirable weight gain, contrary to popular belief
A trial involving Michigan Medicine researchers has upended a long-held belief that adenotonsillectomies for children with mild sleep-disordered breathing lead to undesirable weight gain.
bone close up of cells inside green bbble with cells inside in yellow brown pink and red orange background
Health Lab
How breast cancer cells survive in bone marrow after remission
A new study from researchers at the University of Michigan and the University of California San Diego has shed light on a previously poorly understood aspect of breast cancer recurrence: how cancer cells survive in bone marrow despite targeted therapies.
patient looking at paper with provider in scrubs blue in clinic
Health Lab
How race impacts patients’ response to cancer immunotherapy
The first large scale analysis finds immune checkpoint inhibitors are equally effective in Black and white patients, with Black patients having fewer side effects.
emergency sign wording in red on brick building
Health Lab
Refining tools that spot risk of violence in young adults in urban ERs may save lives
Half of young adult patients treated in emergency departments in three urban hospitals across the country reported experiencing violence either as a victim or aggressor, including firearm violence, in the six months prior to seeking treatment, according to a University of Michigan study.
see through blue person with red lines running through neck to chest
Health Lab
What is phrenic neuropathy?
Phrenic neuropathy is a condition that impacts the nerve around the diaphragm making it harder to breathe, especially in situations such as lying down or being in water. The condition is treatable, with surgical intervention, physical therapy or by letting it heal over time.
Microscope
Health Lab
Nerve damage reduced in prediabetic mice with diet, exercise
A low calorie diet and high intensity exercise can reduce nerve damage in prediabetic mice, according to a Michigan Medicine study.